Natera(US:NTRA)2026-02-26 22:30Financial Data and Key Metrics Changes - The company processed approximately 924,000 tests in Q4 2025, with MRD clinical unit growth reaching 225,000 tests, a 56% increase compared to Q4 2024 [5][10] - Revenue for the quarter was around $666 million, representing a 40% growth year-over-year [5][6] - Gross margin for Q4 was reported at 66.9%, exceeding expectations and reflecting strong operational performance [5][11] - Cash flow generated in 2025 was over $107 million, with expectations for continued strong cash flow in 2026 [6][29] Business Line Data and Key Metrics Changes - The MRD product portfolio was significantly expanded with the launch of the genome version of Signatera and the Latitude MRD test [9][25] - The Fetal Focus single gene NIPT test was launched, addressing unmet clinical needs and showing robust performance metrics [12][14] - The organ health portfolio, particularly the Prospera donor DNA monitoring, continues to evolve, with significant investments aimed at improving clinical utility [16][18] Market Data and Key Metrics Changes - Over 50% of oncologists in the U.S. ordered a Signatera test in Q4, indicating strong adoption of MRD testing in clinical practice [10] - The company anticipates continued growth in women's health volumes and ASPs, with a strong start in Q1 2026 [32][62] - The organ health products are expected to maintain a growth trend, driven by the increasing relevance of cell-free DNA in patient care [62] Company Strategy and Development Direction - The company plans to invest in R&D while holding SG&A stable, focusing on targeted investments to drive future growth [6][36] - There is a strong emphasis on expanding reimbursement coverage for Signatera, with ongoing efforts to secure broader Medicare reimbursement [12][30] - The integration of AI-enabled workflows is expected to enhance operational efficiency and reimbursement processes [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operational and financial outlook for 2026, expecting revenue between $2.62 billion and $2.7 billion [6][30] - The company is focused on maintaining a path to profitability while continuing to invest in growth opportunities [29][36] - Management highlighted the importance of generating clinical evidence to support product adoption and market expansion [19][46] Other Important Information - The company has submitted its Latitude MRD assay to MolDX for colorectal cancer, which is expected to enhance MRD assessment capabilities [24][25] - The phased variant technology integrated into the Signatera platform is anticipated to improve detection sensitivity significantly [25][26] Q&A Session Summary Question: Can you discuss the net ASP impact from changes in Medicare rates? - Management indicated that changes in ADLT rates and bundle rates roughly net each other out, with continued execution on reimbursement for covered services expected to drive ASP growth [38] Question: What is the current mix of Signatera by indication? - The majority of Signatera volume is currently from CRC, but management expects other tumor types like breast and lung to gain traction, potentially normalizing the mix over time [66] Question: What are the expectations for women's health market share in 2025? - The company reported a record year in women's health and anticipates further growth with the introduction of the Fetal Focus test, which is expected to attract new customers [82]